

# **ADD** TP: Rs 73,200 | ▲ 7% MRF

Auto Components

06 November 2020

# Strong Q2; earnings estimates raised

MRF delivered a positive surprise on Q2FY21 revenue and earnings, led by strong replacement demand in Indian markets and above-expected operating efficiency. Revenue was up 6% YoY and operating margin expanded 670bps YoY. We raise FY21/FY22/FY23 earnings by 8%/3%/6% to bake in strong replacement demand, OEM segment revival and better margins, yielding a higher Sep'21 TP of Rs 73,200 (vs. Rs 67,000), set at 23x one-year fwd EPS (22x earlier). Maintain ADD as the 13% rally over the past month limits upsides.

**Healthy Q2:** MRF's revenue came in 7% ahead of our estimate at Rs 41.9bn (+6% YoY). Gross margin was better than expected, improving 370bps YoY (+430bps QoQ), while better operating efficiencies further supported EBITDA performance (+58% YoY to Rs 8.5bn). EBITDA margin expanded 670bps YoY and was ahead of our estimate at 20.4% (16.8% est.). Adj. PAT increased 83% YoY to Rs 4bn.

**Replacement demand to fuel growth:** We expect MRF to post a 9% revenue CAGR during FY20-FY23, anchored by its strong brand, >70% revenue share from the replacement segment and expected recovery in auto sector demand. We estimate a healthy volume CAGR of 10% in MHCV and LCV tyres (60% of domestic revenues) and 9% in PV tyres (21% share) for the company over our forecast period, alongside stable EBITDA margins of 15-16%.

**Upgrade earnings, maintain ADD:** Restrictions on Chinese tyre imports should fuel strong replacement demand, aiding margins. We raise FY21/FY22/FY23 earnings by 8%/3%/6% and increase our Sep'21 TP to Rs 73,200, based on a higher 23x target P/E. The stock has rallied 13% over the last one month, taking valuations to 23x/20x FY22E/FY23E EPS which limits upsides. Retain ADD.

### **KEY FINANCIALS**

Y/E 31 Mar	FY19A	FY20A	FY21E	FY22E	FY23E
Total revenue (Rs mn)	158,370	159,911	154,695	188,628	208,497
EBITDA (Rs mn)	22,504	23,237	24,959	29,060	32,483
Adj. net profit (Rs mn)	10,969	13,950	10,689	12,792	14,222
Adj. EPS (Rs)	2,587.0	3,290.0	2,520.9	3,017.0	3,354.3
Adj. EPS growth (%)	0.4	27.2	(23.4)	19.7	11.2
Adj. ROAE (%)	10.3	11.6	8.2	8.9	9.1
Adj. P/E (x)	26.5	20.8	27.2	22.7	20.4
EV/EBITDA (x)	13.5	13.1	11.9	10.0	9.1

Source: Company, BOBCAPS Research

#### BOB Capital Markets Ltd is a wholly owned subsidiary of Bank of Baroda

Important disclosures, including any required research certifications, are provided at the end of this report.

Mayur Milak | Nishant Chowhan, CFA research@bobcaps.in

Ticker/Price	MRF IN/Rs 68,517
Market cap	US\$ 3.9bn
Shares o/s	4mn
3M ADV	US\$18.3mn
52wk high/low	Rs 73,566/Rs 49,915
Promoter/FPI/DII	28%/5%/14%
Source: NSE	

### STOCK PERFORMANCE



Source: NSE





# FIG 1 – QUARTERLY PERFORMANCE

(Rs mn)	Q2FY21	Q2FY20	YoY (%)	Q1FY21	Q₀Q (%)	H1FY21	H1FY20	Y₀Y (%)
Net Revenues	41,864	39,476	6.0	24,306	72.2	66,169	83,571	(20.8)
Total Income (A)	41,864	39,476	6.0	24,306	72.2	66,169	83,571	(20.8)
Operating Expenses:								
Raw materials consumed	23,334	23,470	(0.6)	14,585	60.0	37,919	50,432	(24.8)
Employee Expenses	3,331	3,300	0.9	3,098	7.5	6,429	6,385	0.7
Other Expenses	6,654	7,299	(8.8)	3,309	101.1	9,962	15,318	(35.0)
Total Expenditure (B)	33,319	34,068	(2.2)	20,991	58.7	54,310	72,135	(24.7)
EBITDA (A-B)	8,544	5,408	58.0	3,315	157.7	11,860	11,436	3.7
Other Income	443	948	(53.3)	430	2.9	873	1,997	(56.3)
Depreciation	2,839	2,372	19.7	2,730	4.0	5,569	4,652	19.7
EBIT	6,148	3,984	54.3	1,016	505.1	7,164	8,781	(18.4)
Finance Costs	528	665	(20.6)	737	(28.4)	1,265	1,347	(6.1)
PBT before excep items	5,620	3,319	69.4	279	1,914.4	5,899	7,434	(20.6)
PBT after excep items	5,620	3,319	69.4	279	1,914.4	5,875	7,422	(20.8)
Tax expense	1,590	1,115	42.6	109	1,365.4	1,699	2,545	(33.3)
Reported PAT	4,030	2,204	82.9	171	2,263.8	4,177	4,877	(14.3)
Adjusted PAT	4,030	2,204	82.9	171	2,263.8	4,201	4,889	(14.1)

Source: Company, BOBCAPS Research

# FIG 2 - KEY PARAMETERS

(%)	Q2FY21	Q2FY20	YoY (bps)	Q1FY21	QoQ (bps)	H1FY21	H1FY20	YoY (bps)
Gross Margin	44.3	40.5	371	40	427	42.7	39.7	304
EBITDA Margin	20.4	13.7	671	14	677	17.9	13.7	424
EBIT Margin	14.7	10.1	459	4	1,051	10.8	10.5	32
PBT Margin	13.4	8.4	502	1	1,228	8.9	8.9	2
Tax Rate	28.3	33.6	(531)	39	(1,060)	28.9	34.3	(538)
Adj PAT Margin	9.6	5.6	405	1	893	6.3	5.8	50

Source: Company, BOBCAPS Research



# Valuation methodology

Restrictions on Chinese tyre imports should fuel strong replacement demand, aiding margins. We raise our FY21/FY22/FY23 earnings estimates by 8%/3%/6% and expect a revenue/EBITDA/PAT CAGR of 9%/11%/11% for MRF over FY20-FY23 (excludes DTA benefit of ~Rs 4bn in FY20). Our Sep'21 target price stands revised to Rs 73,200 (vs. Rs 67,000), set at 23x one-year forward EPS (22x earlier). The stock has rallied 13% over the last one month, taking valuations to 23x/20x FY22E/FY23E EPS which limits upsides. Maintain ADD.

## FIG 3 – REVISED ESTIMATES

Change (%)	FY21E	FY22E	FY23E
Revenues	0.0	0.0	0.0
EBITDA	10.9	4.1	4.1
OPM (bps)	159	61	61
Adj. PAT	8.3	2.5	6.0
EPS	8.3	2.5	6.0

Source: Company, BOBCAPS Research



### FIG 4 – RELATIVE STOCK PERFORMANCE

Source: NSE

# Key risks

- Slower recovery in OE demand may adversely impact sales.
- A spike in prices of natural rubber or crude derivatives could hurt margins.



### FINANCIALS

#### Income Statement

Income Statement					
Y/E 31 Mar (Rs mn)	FY19A	FY20A	FY21E	FY22E	FY23E
Total revenue	158,370	159,911	154,695	188,628	208,497
EBITDA	22,504	23,237	24,959	29,060	32,483
Depreciation	8,063	9,806	11,420	13,545	15,882
EBIT	18,616	16,736	16,536	18,939	20,579
Net interest income/(expenses)	(2,528)	(2,743)	(2,246)	(1,838)	(1,566)
Other income/(expenses)	4,175	3,305	2,996	3,424	3,978
Exceptional items	(1,356)	0	0	0	C
EBT	14,733	13,993	14,290	17,102	19,014
Income taxes	5,120	43	3,601	4,310	4,79
Extraordinary items	0	0	0	0	C
Min. int./Inc. from associates	0	0	0	0	C
Reported net profit	9,613	13,950	10,689	12,792	14,222
Adjustments	1,356	0	0	0	C
Adjusted net profit	10,969	13,950	10,689	12,792	14,222
	23,276	23,401	23,300	31,448	29,764
Y/E 31 Mar (Rs mn)	FY19A	FY20A	FY21E	FY22E	FY23E
Accounts payables	,	,	,	,	,
Other current liabilities	21,389	24,404	23,405	35,570	33,60
Provisions	1,571	3,422	3,422	3,422	3,422
Debt funds	18,675	10,210	10,210	10,210	8,210
Other liabilities	2,441	5,781	5,781	5,781	5,78
Equity capital	42	42	42	42	42
Reserves & surplus	106,491	120,001	130,614	143,104	156,99
Shareholders' fund	106,533	120,044	130,656	143,147	157,034
Total liabilities and equities	173,885	187,263	196,775	229,579	237,812
Cash and cash eq.	601	11,069	3,987	3,699	4,733
Accounts receivables	23,616	22,570	24,751	32,067	31,275
Inventories	29,509	28,527	29,392	39,612	37,530
Other current assets	1,775	151	464	566	52
Investments	38,484	15,402	21,402	21,402	23,402
Net fixed assets	67,675	88,492	97,072	113,527	122,645
CWIP	14,032	17,346	16,000	15,000	14,000
Intangible assets	0	0	0	0	(
Deferred tax assets, net	(8,392)	(4,278)	(4,278)	(4,278)	(4,278
<u></u>	. =	=	=	= 0.05	

6,585

173,885

7,985

187,263

7,985

196,775

7,985

229,579

7,985

237,812

Source: Company, BOBCAPS Research

Other assets
Total assets

Y/E 31 Mar (Rs mn)	FY19A	FY20A	FY21E	FY22E	FY23E
Net income + Depreciation	17,676	23,756	22,108	26,337	30,104
Interest expenses	2,528	2,743	2,246	1,838	(1,566)
Non-cash adjustments	(4,175)	(3,305)	(2,996)	(3,424)	(3,978)
Changes in working capital	(7,962)	10,584	(4,460)	2,677	(734)
Other operating cash flows	1,356	0	0	0	0
Cash flow from operations	9,422	33,778	16,899	27,427	23,826
Capital expenditures	(18,228)	(33,937)	(18,654)	(29,000)	(24,000)
Change in investments	2,980	23,082	(6,000)	0	(2,000)
Other investing cash flows	4,175	3,305	2,996	3,424	3,978
Cash flow from investing	(11,073)	(7,549)	(21,658)	(25,576)	(22,022)
Equities issued/Others	0	0	0	0	C
Debt raised/repaid	1,669	(8,465)	0	0	(2,000)
Interest expenses	(2,528)	(2,743)	(2,246)	(1,838)	(1,566)
Dividends paid	0	(509)	(76)	(302)	(335)
Other financing cash flows	1,724	(4,044)	0	0	C
Cash flow from financing	866	(15,761)	(2,322)	(2,140)	(3,901)
Changes in cash and cash eq.	(786)	10,468	(7,081)	(288)	(2,097)
Closing cash and cash eq.	601	11,069	3,987	3,699	4,733

## Per Share

Y/E 31 Mar (Rs)	FY19A	FY20A	FY21E	FY22E	FY23E
Reported EPS	2,587.0	3,290.0	2,520.9	3,017.0	3,354.3
Adjusted EPS	2,587.0	3,290.0	2,520.9	3,017.0	3,354.3
Dividend per share	0.0	100.0	17.8	71.2	79.1
Book value per share	25,125.7	28,312.1	30,815.2	33,761.0	37,036.2

## Valuations Ratios

Y/E 31 Mar (x)	FY19A	FY20A	FY21E	FY22E	FY23E
EV/Sales	1.9	1.9	1.9	1.5	1.4
EV/EBITDA	13.5	13.1	11.9	10.0	9.1
Adjusted P/E	26.5	20.8	27.2	22.7	20.4
P/BV	2.7	2.4	2.2	2.0	1.8

# **DuPont Analysis**

Y/E 31 Mar (%)	FY19A	FY20A	FY21E	FY22E	FY23E
Tax burden (Net profit/PBT)	74.4	99.7	74.8	74.8	74.8
Interest burden (PBT/EBIT)	79.1	83.6	86.4	90.3	92.4
EBIT margin (EBIT/Revenue)	11.8	10.5	10.7	10.0	9.9
Asset turnover (Revenue/Avg TA)	130.5	121.3	109.4	123.4	126.3
Leverage (Avg TA/Avg Equity)	1.2	1.2	1.1	1.1	1.1
Adjusted ROAE	10.8	12.3	8.5	9.3	9.5

Source: Company, BOBCAPS Research | Note: TA = Total Assets



Ratio Analysis					
Y/E 31 Mar	FY19A	FY20A	FY21E	FY22E	FY23E
YoY growth (%)					
Revenue	7.2	1.0	(3.3)	21.9	10.5
EBITDA	1.0	3.3	7.4	16.4	11.8
Adjusted EPS	0.4	27.2	(23.4)	19.7	11.2
Profitability & Return ratios (%)					
EBITDA margin	14.2	14.5	16.1	15.4	15.6
EBIT margin	11.8	10.5	10.7	10.0	9.9
Adjusted profit margin	6.9	8.7	6.9	6.8	6.8
Adjusted ROAE	10.3	11.6	8.2	8.9	9.1
ROCE	9.4	12.0	8.5	9.0	9.1
Working capital days (days)					
Receivables	52	53	56	55	55
Inventory	59	66	68	67	68
Payables	76	90	95	89	90
Ratios (x)					
Gross asset turnover	0.6	0.8	0.9	0.9	1.0
Current ratio	1.2	1.2	1.2	1.1	1.1
Net interest coverage ratio	7.4	6.1	7.4	10.3	13.1
Adjusted debt/equity	0.2	0.1	0.1	0.1	0.1

Source: Company, BOBCAPS Research



# Disclaimer

#### Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%


ADD - Expected return from >+5% to +15%

**REDUCE –** Expected return from -5% to +5%

SELL - Expected return <-5%

Note: Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

#### RATINGS AND TARGET PRICE (3-YEAR HISTORY): MRF (MRF IN)



B – Buy, A – Add, R – Reduce, S – Sell

#### **Rating distribution**

As of 31 October 2020, out of 88 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 42 have BUY ratings, 14 have ADD ratings, 10 are rated REDUCE and 22 are rated SELL. None of these companies have been investment banking clients in the last 12 months.

#### Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

#### General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH00000040 valid till 03 February 2020. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations



expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

#### Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company in the past 12 months. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.